Summary
24.88 -0.18(-0.72%)10/15/2024
Avantor Inc. (AVTR)
Avantor Inc. (AVTR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.72 | 0.24 | -8.55 | 19.50 | 0.69 | 15.33 | 80.55 | 71.59 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.88 | |
| Open | 24.91 | |
| High | 25.46 | |
| Low | 24.86 | |
| Volume | 4,054,223 | |
| Change | -0.18 | |
| Change % | -0.72 | |
| Avg Volume (20 Days) | 4,090,768 | |
| Volume/Avg Volume (20 Days) Ratio | 0.99 | |
| 52 Week Range | 16.63 - 28.00 | |
| Price vs 52 Week High | -11.14% | |
| Price vs 52 Week Low | 49.61% | |
| Range | -0.12 | |
| Gap Up/Down | -0.30 | |
Fundamentals | ||
| Market Capitalization (Mln) | 17,717 | |
| EBIDTA | 1,396,999,936 | |
| PE Ratio | 48.4577 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 45.37 | |
| Book Value | 5.0890 | |
| Earnings Per Share | 0.7910 | |
| EPS Estimate Current Quarter | 0.3200 | |
| EPS Estimate Next Quarter | 0.3300 | |
| EPS Estimate Current Year | 1.3900 | |
| EPS Estimate Next Year | 1.5400 | |
| Diluted EPS (TTM) | 0.7910 | |
| Revenues | ||
| Profit Marging | 0.0729 | |
| Operating Marging (TTM) | 0.1403 | |
| Return on asset (TTM) | 0.0576 | |
| Return on equity (TTM) | 0.1593 | |
| Revenue TTM | 7,269,400,064 | |
| Revenue per share TTM | 12.4740 | |
| Quarterly Revenue Growth (YOY) | 0.1430 | |
| Quarterly Earnings Growth (YOY) | 2.1400 | |
| Gross Profit (TTM) | 2,080,500,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 48.4577 | |
| Forward PE | 24.9377 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.7334 | |
| Revenue Enterprise Value | 4.0095 | |
| EBITDA Enterprise Value | 23.7117 | |
| Shares | ||
| Shares Outstanding | 609,452,992 | |
| Shares Float | 605,363,298 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.63 | |
| Institutions (%) | 94.54 | |
10/02 12:46 EST - zacks.com
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
09/30 08:05 EST - prnewswire.com
Avantor® Wins Kaizen Institute Award for Excellence in Process Improvement and Quality Management
Recognition highlights commitment to Avantor Business System (ABS) principles to enhance customer experience RADNOR, Pa. , Sept. 30, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today that the Company's NuSil brand has received the 2024 North American Daily Kaizen Management award from the Kaizen Institute.
Avantor® Wins Kaizen Institute Award for Excellence in Process Improvement and Quality Management
Recognition highlights commitment to Avantor Business System (ABS) principles to enhance customer experience RADNOR, Pa. , Sept. 30, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today that the Company's NuSil brand has received the 2024 North American Daily Kaizen Management award from the Kaizen Institute.
09/27 08:05 EST - prnewswire.com
Avantor® to Host Third Quarter 2024 Earnings Call on Friday, October 25, 2024
RADNOR, Pa. , Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m.
Avantor® to Host Third Quarter 2024 Earnings Call on Friday, October 25, 2024
RADNOR, Pa. , Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m.
09/25 09:05 EST - prnewswire.com
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Reflects Growing Commitment to Renewable Energy Sources Energize virtual power purchase agreement will provide the equivalent of 25GWh of renewable energy annually beginning in 2026 Avantor continues to implement global solar installations, with more planned in 2025 RADNOR, Pa. , Sept. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, has entered into a 10-year virtual power purchase agreement through the Energize program, a first of its kind initiative to increase access to renewable energy for pharmaceutical supply chains.
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Reflects Growing Commitment to Renewable Energy Sources Energize virtual power purchase agreement will provide the equivalent of 25GWh of renewable energy annually beginning in 2026 Avantor continues to implement global solar installations, with more planned in 2025 RADNOR, Pa. , Sept. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, has entered into a 10-year virtual power purchase agreement through the Energize program, a first of its kind initiative to increase access to renewable energy for pharmaceutical supply chains.
09/23 08:05 EST - prnewswire.com
Avantor® Participates in BioProcess International 2024 Conference Scientific Program and Exhibition
RADNOR, Pa. , Sept. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the Company will deliver multiple scientific presentations and exhibit at BioProcess International 2024, scheduled for September 23-26 in Boston.
Avantor® Participates in BioProcess International 2024 Conference Scientific Program and Exhibition
RADNOR, Pa. , Sept. 23, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the Company will deliver multiple scientific presentations and exhibit at BioProcess International 2024, scheduled for September 23-26 in Boston.
09/13 04:00 EST - seekingalpha.com
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry recovery. Baxter's shares increased significantly post-earnings, demonstrating portfolio durability and organic growth, prompting us to accumulate shares at attractive valuations.
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry recovery. Baxter's shares increased significantly post-earnings, demonstrating portfolio durability and organic growth, prompting us to accumulate shares at attractive valuations.
09/12 08:05 EST - prnewswire.com
Avantor® Achieves Bronze Medal from EcoVadis for Sustainability Performance
EcoVadis Rating validates Avantor's business sustainability commitments and performance RADNOR, Pa. , Sept. 12, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today, for the second year in a row, that the Company has been awarded a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.
Avantor® Achieves Bronze Medal from EcoVadis for Sustainability Performance
EcoVadis Rating validates Avantor's business sustainability commitments and performance RADNOR, Pa. , Sept. 12, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced today, for the second year in a row, that the Company has been awarded a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.
08/22 08:05 EST - prnewswire.com
Avantor® to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
RADNOR, Pa. , Aug. 22, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5, at approximately 10:45 a.m.
Avantor® to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
RADNOR, Pa. , Aug. 22, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5, at approximately 10:45 a.m.
08/19 12:00 EST - zacks.com
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
08/16 07:35 EST - prnewswire.com
Avantor® Enters into Definitive Agreement to Divest Clinical Services Business to Audax Private Equity
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydown RADNOR, Pa. , Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "Clinical Services"), to Audax Private Equity ("Audax") for a transaction value of approximately $650 million.
Avantor® Enters into Definitive Agreement to Divest Clinical Services Business to Audax Private Equity
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydown RADNOR, Pa. , Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "Clinical Services"), to Audax Private Equity ("Audax") for a transaction value of approximately $650 million.
07/29 13:51 EST - zacks.com
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline.
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline.
07/29 09:11 EST - benzinga.com
Avantor Analysts Increase Their Forecasts After Better-Than-Expected Earnings
Avantor, Inc. AVTR reported better-than-expected second-quarter earnings results on Friday.
Avantor Analysts Increase Their Forecasts After Better-Than-Expected Earnings
Avantor, Inc. AVTR reported better-than-expected second-quarter earnings results on Friday.
07/26 08:15 EST - zacks.com
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.
07/26 06:05 EST - prnewswire.com
Avantor® Reports Second Quarter 2024 Results
Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% Net income of $93 million; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. , July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024.
Avantor® Reports Second Quarter 2024 Results
Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% Net income of $93 million; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. , July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024.
07/23 19:17 EST - prnewswire.com
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600
NEW YORK , July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600
NEW YORK , July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.
07/19 11:05 EST - zacks.com
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/10 13:21 EST - zacks.com
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
07/02 13:21 EST - zacks.com
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
Avantor, Inc. AVTR recently released two innovative products aimed at revolutionizing the gene therapy harvest process. J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease are designed to enhance efficiency, reduce environmental impact, improve operational outcomes and preserve the integrity of viral particles.
Avantor (AVTR) Launches Solutions for Gene Therapy Harvest
Avantor, Inc. AVTR recently released two innovative products aimed at revolutionizing the gene therapy harvest process. J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease are designed to enhance efficiency, reduce environmental impact, improve operational outcomes and preserve the integrity of viral particles.
07/01 08:05 EST - prnewswire.com
Avantor® Announces New J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease
Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.
Avantor® Announces New J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease
Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.
06/28 08:05 EST - prnewswire.com
Avantor® to Host Second Quarter 2024 Earnings Call on Friday, July 26, 2024
RADNOR, Pa. , June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m.
Avantor® to Host Second Quarter 2024 Earnings Call on Friday, July 26, 2024
RADNOR, Pa. , June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m.